On October 31, 2018, a unanimous three-judge panel in the Pennsylvania Superior Court upheld the $2.5 million Risperdal verdict awarded to an Alabama boy, who developed breasts due to the antipsychotic drug.
The case was the first among thousands of other product liability lawsuits filed against J&J. In August 2015, J&J appealed to overturn the verdict awarded to the plaintiff. The plaintiff was on Risperdal to treat his autism-related behavioral issues, and his parents claimed his abnormal breast growth was the result of the drug's side effect.
More than 7,000 Risperdal product liability lawsuits against J&J are filed in the Pennsylvania State Court. Two coordinated actions have been filed for Risperdal cases: one in Los Angeles Superior Court (Risperdal and Invega Product Liability Cases, JCCP 4775) and the other in Philadelphia (In Re: Risperdal Litigation, March 2010 Term, Case No. 100300296).
